Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Gross Profit (2024 - 2025)

X4 Pharmaceuticals' Gross Profit history spans 2 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 94.7% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $29.4 million, up 1567.95%, while the annual FY2025 figure was $29.4 million, 1567.95% up from the prior year.
  • Gross Profit reached $2.2 million in Q4 2025 per XFOR's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $24.1 million in Q1 2025 to a low of $295000.0 in Q2 2024.